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Abstract
Background: The role of uric acid in development of renal dysfunction (RD) remains controversial. Earlier studies
have reported inconsistent results, possibly because of their varying ability to adjust for confounding. The impact of
longitudinal change in uric acid on renal outcome has not been assessed previously. We aimed to study the impact
of change in serum uric acid (SUA) as well as baseline SUA on the development of RD.
Methods: In a prospective cohort study, we assessed the associations between change in SUA during follow-up,
baseline SUA and RD (defined as albumin-creatinine-ratio (ACR) ≥1.13 mg albumin/mmol creatinine and/or eGFR
< 60 ml/min/1.73 m2) in a large cohort from a general population participating in the Tromsø Study (n = 2637).
Participants were stratified according to tertiles of change in SUA between baseline (1994/95) and follow-up
13 years later. (upper tertile: SUA increasing group, two lower tertiles: SUA non-increasing group). Logistic
regression analysis was applied with RD and each component of RD after 7 and 13 years as the dependent
variables. Adjustments were made for baseline eGFR, cardiovascular risk factors, and the use of antihypertensive
drugs including diuretics.
Results: After excluding participants with RD at baseline, SUA increasers, compared to SUA non-increasers, had
a doubled risk of RD after 7 years (odds ratio 2.00, (95 % CI 1.45, 2.75)). Odds ratio for RD in SUA increasers after
13 years was 2.18 (95 % CI 1.71, 2.79). The risk of developing ACR ≥1.13 mg/mmol alone was not significantly
increased after 7 years (odds ratio 1.30 (95 % CI 0.90, 1.89), but after 13 years (odds ratio 1.43 (95 % CI 1.09, 1.86)). An
increase in baseline SUA of 59 μmol/L (1 mg/dL) gave an odds ratio for RD after 13 years of 1.16 (95 % CI 1.04, 1.29).
Conclusion: An increase in SUA during follow-up was associated with an increased risk of developing RD after 7
and 13 years.
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Background
Over the last few decades, chronic kidney disease (CKD)
has emerged as a global health problem of epidemic pro-
portions [1]. The prevalence of end-stage renal disease,
and concomitantly the number of patients on renal re-
placement therapy, is steadily increasing, and these pa-
tients have a 10-fold mortality rate [2]. However, also
lower stages of CKD have a significant impact on the
population health. Estimated glomerular filtration rate
(eGFR) less than 60 mL/min/1.73 m2 and urinary albu-
min creatinine ratio (ACR) of 1.13 mg/mmol or more
are independent predictors of mortality risk in the gen-
eral population [3]. We therefore contend that there is a
need to search for more modifiable risk factors for CKD.
Hyperuricemia has been recognized as a risk factor for
the incidence and progression of CKD, although studies
have reported conflicting results [4]. Studying the role of
SUA in CKD is difficult since uric acid is excreted pri-
marily by the kidneys, and a decrease in GFR will be ac-
companied by a rise in SUA level. However, a Japanese
study recently assessed the impact of SUA on the natural
history of eGFR. The authors claimed that if elevation of
SUA is a result, rather than a cause, of a decline in
eGFR, the relationship between SUA and eGFR should
be the same in the same population over years except
for shifts by age-dependent reduction of eGFR. Multiple
regression analyses showed that explanatory factors of
eGFR after a 6-year interval were age and SUA at base-
line. They concluded that elevation of SUA accelerated
the yearly decline in eGFR [5].
Some evidence suggests that uric acid itself may be
harmful in patients with CKD by contributing to in-
creased inflammation and thus a progression in CKD
[4]. Although controversial, these observations are sup-
ported by large prospective observational studies show-
ing that increased SUA levels predict the development
and progression of CKD in various populations [2, 6–11].
However, several of them do not have information on al-
buminuria as well as the use of allopurinol, diuretics and
other medication which could confound the results. Fur-
thermore, knowledge about the effect of change in SUA
on renal function is scarce. The object of the present study
was to assess whether increased SUA may predispose to
the development of renal dysfunction (RD) in a pro-
spective study in the general population. We also aimed
to assess the possible impact of change in SUA during
observation and examine the association between SUA
and albuminuria.
Methods
The Tromsø Study is an ongoing population based, pro-
spective study with six repeated health surveys in the
municipality of Tromsø, Northern Norway [12]. To the
fourth survey (Tromsø 4) in 1994/95, all inhabitants
aged 25 and above were invited, and 27,158 (77 %) par-
ticipated. All participants aged 55–74 years, and 5–10 %
of the other birth cohorts older than 24 years (10,542
individuals), were invited to a second visit with extensive
examination including blood and urine testing. Attend-
ance rate was 76 % (7965 individuals). Subjects who had
previously taken part in the second visit of Tromsø 4 were
eligible for a second-visit examination also in Tromsø 5
(2001/02), and 5939 subjects participated (85 %). Tromsø
6 was run in 2007/08. A total of 12,983 men and women
aged 30–87 years participated, 65 % of all invited persons.
Similar to Tromsø 4 and 5, a large sample from the
Tromsø 6 cohort was invited to a second visit, and 7307
individuals attended. About 80 % of the participants in
Tromsø 6 had attended Tromsø 4. SUA measurements
were obtained from all of the three surveys. In Tromsø 4,
SUA was measured in 6458 participants. Among these,
SUA was measured in 4967 and 3047 persons in Tromsø
5 and 6, respectively. In this article, we describe the 2637
participants who had SUA measurements in all three sur-
veys. All individuals with baseline measurements who died
before Tromsø 6 or were lost to follow-up for other rea-
sons were excluded. The Regional Committee for Medical
Research Ethics (REC North) approved the study, and all
participants gave informed written consent.
Clinical and laboratory measurements
In each survey the participants responded to a self-
administered questionnaire with information about current
medication, history of cardiovascular disease and diabetes,
smoking habits and physical activity. Height and weight
were measured and body mass index (BMI) calculated
[12]. Blood pressure was recorded with an automatic de-
vice (Dinamap Vital Sign Monitor 1846 Critikon). Three
measurements were made at one minute intervals after
2 min of rest, and the mean of the two final recordings was
used. Hypertension was defined as systolic blood pres-
sure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg
and/or current use of antihypertensive medication. Leisure
physical activity was classified as active (>1 h physical activ-
ity with prominent sweating or breathlessness per week) or
inactive (all others). Smoking habits were classified as non-
smokers or current smokers. SUA was measured by pho-
tometry with COBAS® instruments (Roche diagnostics,
Switzerland) using an enzymatic colorimetric test, the uri-
case/ PAP method. Reference values were140-340 μmol/L
(2.45.7 mg/dl) for females and 200–415 μmol/L (3.4–
7.0 mg/dl) for males. Change in SUA from 1994/95 to
2001/02 was calculated as SUA in Tromsø 5 minus SUA in
Tromsø 4. Similarly, change in SUA from 1994/95 to
2007/08 was calculated.
In the U.S National Health and Nutrition Examination
Survey (NHANES) 2007–2008, hyperuricemia was defined
as SUA >417 μmol/L (7 mg/dL) in men and >339 μmol/L
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(5.7 mg/dL) in women, and the same definition was ap-
plied in the present study [11]. In Tromsø 4 and 5, serum
creatinine was analyzed by a modified Jaffe reaction, but
since creatinine-based estimation of GFR is better vali-
dated for enzymatic creatinine measurements, 111 plasma
samples from Tromsø 4 and 142 samples from Tromsø 5
were thawed and reanalyzed with an enzymatic method
(Modular P/Roche). Values were fitted to a linear re-
gression model, and recalibrated creatinine values were
calculated for all participants. In the Tromsø 6, serum
creatinine was analysed on a Hitachi Modular model
using an enzymatic method that has been standardized
against isotope dilution mass spectroscopy (CREA Plus,
Roche Diagnostics, GmbH, Mannheim, Germany). eGFR
was calculated according to the CKD-EPI equation [13].
Three separate samples of morning spot urine from three
consecutive days were collected and analyzed within 20 h.
Urinary albumin and creatinine were analyzed using kits
from ABX Diagnostics, Montpellier, France. ACR in mg
albumin per mmol creatinine (mg/mmol) was calculated
for each day and the mean of all three was used in the
analyses. Serum cholesterol was analyzed by enzymatic
colorimetric methods with commercial kits (CHOD-PAP;
Boehringer Mannheim, Mannheim, Germany).
Statistical analysis
Data are given as mean (±SD) for (normally distributed)
variables or as median (interquartile range) for vari-
ables with a skewed distributions. Categorical variables
are given as numbers (percentages). Baseline cardiovas-
cular risk profile including current use of antihypertensive
medication, diuretics, proportion of smokers, physical ac-
tivity, BMI, blood pressure, SUA, creatinine, eGFR, and
ACR was compared between the persons who only partici-
pated in the Tromsø 4 study and the participants who also
attended follow-up in 2007/08 (Tromsø 6). Two-tailed
independent groups t-tests were used for normally distrib-
uted variables and Mann-Whitney’s test otherwise. For
categorical variables Chisquare tests were used. Change in
SUA from 1994/95 to 2007/08 was categorized into ter-
tiles. Tertile 1 and 2 were defined as SUA non-increasers,
and tertile 3 was defined as SUA increasers. Several clas-
sical cardiovascular risk factors were compared between
the two groups using independent groups t-tests, Mann-
Whitney’s tests and chi-square tests as appropriate. The
dichotomous variable RD was defined using a modification
of the 2012 KDIGO CKD classification [14]. We chose the
“high normal” albuminuria stage (ACR ≥ 1.13 mg/mmol)
as the cut-off value for pathological urinary albumin excre-
tion. Participants with eGFR < 60 ml/min/1.73 m2 and/or
ACR ≥ 1.13 mg/mmol were considered to have RD. Logis-
tic regression analyses were performed with this variable as
the dependent variable. As independent variables, we in-
cluded the upper versus the two lower tertiles of change in
SUA from 1994/95 to 2007/08 (SUA increasers vs. SUA
non-increasers), baseline values of SUA, eGFR, ACR, age,
mean systolic pressure, smoking, diabetes, BMI, choles-
terol, physical activity, and antihypertensive medication in-
cluding diuretics. ACR was logarithmically transformed in
order to achieve the best fit of the models. In the models,
we also included change in physical activity, start of antihy-
pertensive drugs, and change of smoking habits during ob-
servation time. We also performed logistic regression
analyses with isolated ACR ≥ 1.13 mg/mmol or isolated
GFR < 60 ml/min/1.73 m2 at follow-up as the dependent
variables and the same independent variables as listed
above. All analyses were done for the cohort followed from
1994/95 until 2001/02 and then for the same cohort
followed from 1994/95 until 2007/08. First, the analyses
were done in a subgroup that only included the partici-
pants who did not have RD at baseline. Finally, all the lo-
gistic regression analyses were repeated with the entire
cohort included. The statistical analyses were run using
SPSS software, version 21.0 (SPSS, INC., Chicago, Illinois)
and a two-tailed p value <0.05 was considered statistically
significant.
Results
There were 2637 participants who had measurements of
SUA from all three surveys, Tromsø 4, 5 and 6. Compared
to the participants who attended one or more of the
follow-up surveys, the participants who only attended the
Tromsø 4 Study (1994/95) had a less favorable cardiovas-
cular risk profile (data not shown). They were older, had
higher SUA level, lower eGFR, higher ACR, higher BMI,
and higher cholesterol. There were also more participants
with hypertension, known diabetes, and a history of myo-
cardial infarction and stroke in this cohort.
Cohort characteristics
In the final cohort, 250 men (20 %) and 196 women
(14 %) had hyperuricemia at baseline (Tromsø 4; 1994/
95). Seven years later, in Tromsø 5, the corresponding
percentages were were 16 % and 18 %, respectively,
whereas 17 % of the male and 22 % of the female partici-
pants had hyperuricemia in Tromsø 6 (2007/08). At
baseline, RD (defined as ACR ≥ 1.13 mg/mmol and/or
eGFR < 60 ml/min/1.73 m2) was present in 422 (16 %) of
the participants; 404 (15 %) had ACR ≥ 1.13 mg/mmol
and 32 (1.2 %) had eGFR < 60 ml/min/1.73 m2. After
7 years (Tromsø 5) the number of participants with RD
had increased to 474 (18 %). Among these, 394 (15 % of
the total cohort) had ACR ≥ 1.13 mg/mmol and 117
(4 %) had eGFR < 60 ml/min/1.73 m2. The highest preva-
lence of RD was found in 2007/08 (Tromsø 6), when 697
(26 %) of the participants had the combined endpoint RD;
ACR ≥ 1.13 mg/mmol was found in 589 (22 %) and de-
creased eGFR was present in 220 (8 %) of the participants.
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In the entire cohort, SUA increased only slightly be-
tween the Tromsø 4 and Tromsø 6 studies; mean (± SD)
of SUA change was 7 (±73) μmol/L. However, the large
SD compared to the mean indicated a vast dispersion.
Thus, the SUA change was dichotomized into SUA non-
increasers (two lower tertiles of SUA change), and SUA
increasers (upper tertile of SUA change). The cut-off be-
tween the SUA non-increasers and increasers was a SUA
change during follow-up of 33 μmol/L. In the SUA non-
increaser group, the mean SUA change over 13 years
was −30 (±54) μmol/L, whereas the mean rise in SUA
was 81 (±46) μmol/L in the SUA increaser group. Dur-
ing the first 7 years, the SUA increasers had a mean in-
crease in SUA of 65 (±35) μmol/L whereas the
corresponding 7-year change in SUA for the non-
increasers was −24 (±49) μmol/L.
Table 1 shows characteristics at baseline (1994/95) and
follow-up (2007/08) for the male SUA increasers vs. the
SUA non-increasers. Table 2 shows the same variables at
baseline and follow-up for the females. Both the baseline
and follow-up clinical characteristics showed the same
pattern in men and women. There was no significant
difference in eGFR between SUA increasers and non-
increasers at baseline. At follow-up eGFR had decreased
in both groups, markedly more for SUA increasers. The
proportion of participants with hypertension was higher
among SUA increasers both at baseline and at follow-up.
The use of diuretics was approximately the same in SUA
increasers and non-increasers at baseline. At follow-up
the use of diuretics was markedly higher among SUA in-
creasers. Very few participants (0.2–0.8 %) were using
allopurinol both at baseline and follow-up, and the use
of allopurinol was not an independent predictor for any
renal endpoint. The proportion of current smokers was
similar between the two groups (women) or higher
among SUA increasers than nonincreasers (men) at
baseline, whereas the opposite was found at follow-up.
There were slightly more females than males among
SUA increasers. However, there was no significant inter-
action between gender and SUA change during follow-
up for the prediction of RD. Therefore, the multivariable
analyses were not run gender specific.
Multivariable analyses
The results from the multiple logistic regression analyses
with the dependent variables measured at 7 and 13 years
of follow-up are presented in Fig. 1 and in Table 3. In
the analyses presented in Fig. 1, only participants with-
out RD at baseline were included, whereas all partici-
pants were included in Table 3. When the 422
participants with RD at baseline were excluded, an in-
crease in baseline SUA of 59 μmol/L (corresponds to
1 mg/dL) gave an odds ratio (OR) of RD in Tromsø 6 of
1.16 (95 % confidence interval (CI) 1.04, 1.29). Being a
SUA-increaser gave an OR for RD after 7 years of 2.00
(95 % CI 1.45, 2.75). The corresponding OR for RD after
13 years was 2.18 (95 % CI 1.71, 2.79). Among these par-
ticipants, being a SUA increaser was not significantly as-
sociated with development of albuminuria after 7 years,
but gave an OR for ACR ≥1.13 mg/mmol after 13 years
of 1.43 (95 % CI 1.09, 1.86).
When the entire cohort was studied (i.e. with the sub-
jects with baseline RD included), we found that SUA in-
creasers had a doubled risk of RD after 7 years. Being a
SUA-increaser also was significantly associated with
both the single components of the RD, ACR ≥ 1.13 mg/
mmol and decreased eGFR < 60 ml/min/1.73 m2. After
13 years, the SUA increasers had an OR for RD of 2.12
(95 % CI 1.71, 2.65), and the risk of each component of
the RD was also increased (Table 3). Baseline SUA was
not a risk factor for increased ACR after 7 and 13 years,
nor for RD after 7 years, whether the participants with
baseline RD were excluded or not. However, baseline
SUA was a significant predictor for the combined end-
point RD and for reduced eGFR after 13 years in both
cases. Other baseline risk factors for RD after 7 and
13 years of follow-up were age, BMI, change in blood
pressure, and current smoking. The participants who
started with antihypertensive treatment had an increased
risk for RD after 13 years. When we investigated baseline
SUA as a predictor without adjusting for longitudinal
change in SUA, the associations with the renal endpoints
were not significant.
Discussion
In this prospective study from a large cohort from the
general population we found that being in the highest
tertile of SUA change, corresponding to an increase in
SUA of more than 33 μmol/L over 13 years, was an in-
dependent risk factor for RD defined as slightly in-
creased ACR and/or a moderately reduced eGFR. This
result was consistent whether the population had a long
time follow-up of 13 years or whether the follow-up time
was shorter. Moreover, the results were similar when
participants with baseline RD were excluded. Although
the OR for moderately reduced eGFR was higher than
the OR for ACR ≥1.13 mg/mmol, longitudinally increas-
ing SUA was significantly associated also with the devel-
opment of albuminuria after 13 years. The associations
between baseline SUA and the renal endpoints were not
significant when the longitudinal change in SUA was not
adjusted for. The reason for this is unclear, but it is pos-
sible that the association between baseline SUA and the
renal endpoints within the SUA increaser-and non-
increaser groups, respectively, becomes obscured when
the whole cohort is studied without this group division.
In addition, change in SUA can partly be explained as a
regression to the mean phenomenon, and by adjusting
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Table 1 Clinical characteristics at baseline and after 13 years of follow up of the male participants with and without increase in serum uric acid (SUA). The 4th (1994/95) and the
6th (2007/08) Tromsø Study (n = 1270)
Baseline 1994/95 SUA
non-increasers (n = 920)
SUA increasers
(n = 350)
p-value* Follow-up 2007/08 SUA
non- increasers (n = 920)
SUA increasers
(n = 350)
p-value**
Age (years) 56 ± 9 58 ± 8 <0.001 69 ± 9 71 ± 8 <0.001
SUA (μmol/L) 373 ± 81 320 ± 62 <0.001 330 ± 61 403 ± 77 <0.001
Estimated GFR (ml/min/1.73 m2) 96 ± 12 95 ± 11 0.17 85 ± 14 78 ± 17 <0.001
Annual change in estimated GFR (ml/min/1.73 m2) - - - −0.87 ± 0.71 −1.30 ± 0.93 <0.001
ACR (mg/mmol) 0.45 (0.33, 0.80) 0.52 (0.35, 0.86) 0.02 0.46 (0.22, 0.99) 0.60 (0.27, 1.49) <0.001
Systolic blood pressure (mmHg) 139 ± 17 144 ± 19 <0.001 145 ± 21 148 ± 21 0.05
Hypertension, n (%) 464 (50) 216 (62) <0.001 673 (73) 288 (82) <0.001
Body mass index (kg/m2) 26.3 ± 3.0 25.9 ± 2.6 0.03 27.2 ± 3.5 27.4 ± 3.3 0.10
Cholesterol (mmol/L) 6.56 ± 1.19 6.50 ± 1.10 0.3 5.45 ± 1.16 5.40 ± 1.1 0.7
Current smokers, n (%) 239 (27) 112 (32) 0.03 144 (16) 36 (11) 0.04
Physical activity, n(%) 301 (33) 122 (35) 0.9 268 (29) 91 (32) 0.23
Antihypertensives incl. diuretics, n (%) 94 (10) 40 (11) 0.5 94 (10) 40 (11) <0.001
Diuretics, n (%) 4 (0.3) 1 (0.3) 0.9 55 (6) 43 (13) 0.001
Diabetes, n (%) 14 (1.5) 5 (1.4) 0.9 116 (13) 43 (12) 0.9
Previous myocardial infarction and/or stroke, n(%) 66 (7) 21 (6) 0.5 - - -
Started antihypertensive treatment during the observation time, n (%) 279 (30) 158 (45) <0.001
Stopped smoking during the observation time, n (%) 113 (12) 77 (22) <0.001
Became physically active during the observation time, n (%) 126 (14) 41 (12) 0.4
Values are given as mean (standard deviation), median (interquartile range) and number (percentages) as appropriate. ACR: urinary albumin/creatinine ratio. P-values for differences between the SUA increasers and
non-increasers at baseline* and follow-up**
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Table 2 Clinical characteristics at baseline and at 13 years of follow up of the female participants with and without increase in serum uric acid. The 4th (1994/95) and the 6th
(2007/08) Tromsø study (n = 1367)
Baseline 1994/95 SUA
non- increasers (n = 836)
SUA Increasers
(n = 531)
p-value* Follow-up 2007/08 SUA
non- Increasers (n = 836)
SUA-increasers
(n = 531)
p-value**
Age 57 ± 10 58 ± 9 0.17 70 ± 10 70 ± 9 0.17
SUA (μmol/L) 280 ± 67 253 ± 57 <0.001 264 ± 56 332 ± 74 <0.001
Estimated GFR (ml/min/1.73 m2) 95 ± 13 94 ± 14 0.35 85 ± 13 79 ± 18 <0.001
Annual change in estimated GFR (ml/min/1.73 m2) - - −0.76 ± 0.72 −1.2 ± 0.99 <0.001
ACR (mg/mmol) 0.54 (0.38, 0.82) 0.56 (0.39,0.86) 0.42 0.48 (0.27, 0.87) 0.56 (0.29, 1.16) 0.01
Mean systolic blood pressure (mmHg) 138 ± 21 142 ± 23 0.002 148 ± 27 148 ± 25 1.0
Hypertension, n (%) 378 (45) 270 (51) 0.04 596 (71) 414 (77) 0.06
Body mass index (kg/m2) 25.5 ± 3.8 25.8 ± 4.1 0.09 26.3 ± 4.26 27.8 ± 4.8 <0.001
Cholesterol (mmol/L) 6.73 ± 1.34 6.68 ± 1.27 0.6 5.88 ± 1.07 5.95 ± 1.17 0.20
Current smokers, n (%) 216 (26) 147 (28) 0.45 142 (18) 65 (13) 0.02
Physical activity,n (%) 179 (21) 99 (17) 0.04 192 (23) 107 (20) 0.5
Antihypertensives incl. diuretics, n (%) 70 (8) 57 (11) 0.14 70 (8) 57 (10) 0.14
Diuretics, n (%) 6 (0.7) 7 (1.3) 0.3 44 (6) 96 (19) <0.001
Diabetes, n (%) 14 (1.5) 15 (2.6) 0.15 75 (9) 60 (11) 0.2
Previous myocardial infarction and/or stroke, n (%) 25 (3) 6 (1) 0.002 - - -
Started antihypertensive treatment during the observation time, n (%) - - - 230 (28) 212 (46) <0.001
Stopped smoking during the observation time, n (%) - - - 85 (10) 86 (16) 0.001
Became physically active during the observation time, n (%) - - - 126 (15) 71 (13) 0.4
Values presented as in Table 1. ACR: urinary albumin/creatinine ratio. P-values for differences between the SUA increasers and non-increasers at baseline* and follow-up**
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baseline SUA for longitudinal change in the same vari-
able, the influence of random outliers may have been re-
duced. Thus, it may be important to evaluate change in
SUA in addition to one single raised value when consid-
ering the impact of SUA on renal endpoints. In our
study, SUA increase was associated with worsening
eGFR and ACR over time, and these two markers inde-
pendently predict advanced stage CKD, cardiovascular
disease and mortality [15–24].
Numerous reports suggest SUA as a risk factor for CKD
and cardiovascular disease [2, 4, 25–28]. The largest study
evaluated 177,570 patients in the US Renal Data System
(USRDS), where the subjects were followed over 24 years
[10]. Patients in the highest quartile of SUA had a hazard
ratio of 2.14 for CKD. Obermayr et al. followed 21,475
healthy volunteers for 7 years [2]. After adjustment for
baseline eGFR, a slightly elevated SUA level (7–8.9 mg/dl)
was associated with a nearly doubled risk of incident CKD
(eGFR <60 ml/min per 1.73 m2) and an elevated SUA of
more than 9 mg/dl was associated with a tripled risk. This
increased risk remained significant even after adjustment
for baseline eGFR, gender, age, antihypertensive drugs,
and components of the metabolic syndrome. In the Ath-
erosclerosis Risks in Communities (ARIC) Study and the
Cardiovascular Health Study [11], Weiner et al. pooled
two community-based cohorts from the US. Each increase
of 1 mg/dL in SUA was associated with a 7–11 % increase
in incident of CKD. Weiner et al. point out two main limi-
tations in their study: lack of information on baseline
proteinuria and allopurinol use. In the study by Obermayr
et al. [22], proteinuria was included. However, neither of
them included ACR in their analyses. In the Tromsø
Study, three urine specimens were collected and the mean
ACR value was used, reducing the impact of the day-to-
day variation. Also, the use of allopurinol was registered.
However, there were few allopurinol-users included in
the study. Moreover; the use of allopurinol was not a
significant predictor in the univariable analyses and
therefore not included in the multivariable models.
In a recently published meta-analysis that included fif-
teen unique cohorts, the investigators demonstrated a
positive association between SUA levels and the risk of
CKD, defined as eGFR <60 mL/min/1.73 m2 at the follow-
up examination, in middle-aged patients, independent of
established metabolic risk factors. They conclude that fu-
ture randomized, high-quality clinical trials are warranted
to determine whether lowering SUA levels is beneficial in
CKD [29]. Our study is in concordance with the results
from this meta-analysis. However, the positive association
in the meta-analysis was more pronounced among groups
with a mean age < 60 years, and no association was ob-
served in cohorts with a mean age ≥60 years. The present
study included participants in a wide range of age, from
25 to 74 years, but the mean age at baseline was 56 years.
Thus, we found an association among participants who
were older than the cohorts included in the meta-analysis,
and it is possible that our results would have been stron-
ger if mainly younger persons were investigated.
Fig. 1 Odds ratios for renal dysfunction and its components after 7 and 13 years of follow-up in serum uric acid (SUA) increasers compared to SUA
non-increasers. Only participants without renal dysfunction at baseline (n = 2215) are included
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Table 3 Odds ratios for having renal dysfunction after 7 and 13 years of observation when participants with baseline RD were not excluded (n = 2637)
Risk factors Renal dysfunction° Tromsø 5
2001/02 (n = 474)
p-value ACR≥ 1.13 mg/mmol
Tromsø 5 2001/02 (n = 394)
p- value Estimated GFR <60 ml/min/1.73 m2
Tromsø 5, 2001/02 (n = 117)
p- value
Age, per 5 years increase 1.13 (1.02, 1.25) 0.02 1.19 (1.06, 1.33) 0.002 1.44 (1.15, 1.80) <0.001
SUA increasersa 1.98 (1.52, 2.59) <0.001 1.35 (1.018, 1.82) 0.044 4.85 (2.87, 8.19) <0.001
Baseline SUA, per 59 μmol/L (1 mg/dl) increase 1.10 (0.99, 1.24) 0.09 1.05 (0.92, 1.18) 0.5 1.42 (1.15, 1.75) 0.001
Estimated GFR per 5 ml/1.73 m2 decrease 1.22 (1.17, 1.27) <0.001 1.05 (0.99, 1.12) 0.16 1.44 (1.38, 1.49) <0.001
Log ACR per unit 26.9 (18.3, 39.7) <0.001 44.87 (29.57, 68.08) <0.001 1.47 (0.86, 2.49) 0.16
Renal dysfunction Tromsø 6 2007/08 (n = 697) ACR≥ 1.13 mg/mmol Tromsø
6 2007/08 (n = 589)
Estimated GFR < 60 ml/min/1.73 m2
Tromsø 6, 2007/08 (n = 220)
Age, per 5 years increase 1.27 (1.17, 1.38) <0.001 1.31 (1.19, 1.43) <0.001 1.65 (1.39, 1.94) <0.001
SUA increasersa 2.12 (1.71, 2.65) <0.001 1.46 (1.16, 1.85) <0.001 5.11 (3.45, 7,56) <0.001
Baseline SUA, per 59 μmol/L (1 mg/dl) increase 1.15 (1.05, 1.26) 0.003 1.09 (0.99, 1.21) 0.09 1.35 (1.16, 1.58) <0.001
Estimated GFR per 5 ml/1.73 m2 decrease 1.11 (1.06, 1.16) <0.001 0.98 (0.92, 1.03) 0.5 1.38 (1.33, 1.43) <0.001
Log ACR per unit 6.99 (5.16, 9.48) <0.001 11.11(8.05, 15.32) <0.001 1.60 (1.06, 2.41) 0.03
ACR urinary albumin/creatinine ratio, SUA serum uric acid. °Renal dysfunction was defined as ACR ≥1.13 mg/mmol and/or estimated GFR <60 ml/min/1.73 m2. aSUA increasers: the upper tertile of change in SUA from
baseline to follow-up, compared to the two lower tertiles. Multivariate adjustments were performed for systolic blood pressure, BMI, cholesterol, current smoking; physical activity, antihypertensive drugs included
diuretics, diabetes, previous myocardial infarction and/or stroke and change in systolic blood pressure during follow-up. We also included start of antihypertensive treatment during observation, cessation of smoking
during observation or becoming physically active during observation as independent variables
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Most studies use eGFR <60 mL/min/1.73 m2 as the
end-point when considering CKD. We also included
ACR ≥ 1.13 mg/mmol as an outcome, and showed that
increasing SUA also predicted lowgrade albuminuria,
although this association was slightly weakened when
participants with baseline RD were excluded. Accord-
ing to the 2012 Kidney Disease Improving Global
Outcome (KDIGO) CKD classification, we classified
persons with “high normal” ACR (ACR ≥ 1.13 mg/
mmol), as having RD. We chose this cut-off value
since ACR of this magnitude has been shown to pre-
dict cardiovascular disease and mortality in the gen-
eral population [18, 19].
To explain our findings on a basic biological level, sev-
eral studies have investigated the effect of SUA on animals.
Johnson et al. developed a model of hyperuricemia in rats
by providing an uricase inhibitor [30]. The hyperuricemic
rats developed subtle renal injury associated with activa-
tion of the reninangiotensin system and development of
hypertension. Considering human biology, an interesting
biopsy study was recently performed [31]. The association
between SUA level and renal arteriolar hyalinosis and wall
thickening in renal biopsies was assessed in a cross-
sectional study of 167 CKD patients. As the SUA level in-
creased, the degree of hyalinosis and wall thickening
worsened.
The strengths of the present study were the prospect-
ive design, a large cohort from the general population
with a high attendance rate, and a long observation time
(13 years). We were able to adjust for the use of di-
uretics and other medications such as antihypertensive
drugs and allopurinol. We also had ACR measurements
from three unfrozen urine specimens available. In
addition, our study was able to adjust for baseline eGFR,
increasing the likelihood that the RD was a result of in-
creasing SUA and not the other way around. However,
because SUA change was calculated as the difference be-
tween the SUA values at baseline and the last follow-up,
when also the outcome (RD) was assessed simultaneously,
inverse causality between SUA change and decreasing
eGFR is still a possibility.
Other limitations of the present study include the ob-
servational design, which precludes firm conclusions
about causal inferences. As described earlier, only per-
sons with three SUA measurements were included in
the cohort. Analyses showed that the excluded persons
were less healthy at baseline, and this may have influ-
enced the results of the study. However, it is reasonable
to believe that the inclusion of these less healthy individ-
uals would have strengthened rather than weakened the
reported associations. The population included in the
Tromsø Study was mainly Caucasian. The results may
therefore not be generalizable to other populations. How-
ever, increasing number of reports points to SUA as a risk
factor for CKD in various populations including Asians
[7, 8, 26, 27, 32, 33].
Conclusion
In conclusion, the present prospective study shows for
the first time that longitudinally increasing SUA is asso-
ciated with RD, and for each individual components of
RD, i.e. moderately decreased eGFR and slightly increased
ACR. Our study also supports the growing evidence that
SUA is a significant risk factor for CKD. Randomized con-
trolled trials studying SUA decreasing agents are desired
to finally decide whether asymptomatic hyperuricemia
should be treated to reduce the incidence of RD also in
low-risk populations.
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